• Senescent CAFs Drive Breast Cancer Progression

  2026-09-30

  Ye et al. identify a senescent myofibroblast cancer-associated fibroblast population that suppresses natural killer cell activity through its extracellular matrix and thereby promotes breast tumor growth. Genetic and pharmacologic depletion experiments, together with human tumor analyses, support senCAF targeting as a stromal strategy while highlighting important limits for translating mouse findings to clinical therapy.

• BMAL1 Phase Separation and Circadian Transcription

  2026-09-30

  Gao et al. identify BMAL1 as a phase-separating clock protein whose phosphorylated N-terminal intrinsically disordered region supports dynamic transcriptional condensates. The study connects condensate assembly with CLOCK, p300, MED1, E-box DNA, rhythmic gene expression, and locomotor behavior, providing a mechanistic framework for phosphorylation-dependent circadian regulation.

• SAN–Cardiac Plexus Assembloids Model Pacemaker Maturation

  2026-09-29

  This study develops human pluripotent stem cell-derived assembloids that combine sinoatrial node, cardiac ganglionated plexus, and atrial-like tissues to model neuro-cardiac control of pacemaker function. By integrating electrophysiology with human SAN spatial transcriptomics, the authors identify a prosaposin–GPR37 signaling program associated with innervation-dependent pacemaker maturation and conduction dysfunction.

• SB525334 Workflow for ALK5 Signaling Studies

  2026-09-29

  Build a receptor-proximal workflow with SB525334 to connect Smad2/3 signaling measurements to fibrosis, renal injury, and wound-repair phenotypes. The guide translates bone-transport findings in diabetic foot ulcers into practical assay controls while separating validated evidence from recommended assay-development conditions.

• Bicinchoninic Acid Assay (BCA) Kit K4102 Guide

  2026-09-28

  The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit K4102 provides sensitive total-protein measurement for dilute biochemical samples, including many detergent-containing preparations and cell lysates. It is intended for scientific research and sample normalization, not diagnostic, clinical, or medical testing.

• LDN-193189: ALK Inhibitor Workflows for BMP Research

  2026-09-28

  LDN-193189 offers a timed chemical approach to investigate ALK2/ALK3-dependent BMP signaling, from Smad phosphorylation assays to epithelial barrier studies. This practical guide also separates established BMP applications from an HSV-1 neuron-model paper, so assay ideas can transfer without implying an unsupported antiviral mechanism.

• ATRX Loss as a Clue to Glioma Drug Response

  2026-09-27

  ATRX loss may help explain why some high-grade glioma cells respond differently to receptor tyrosine kinase and PDGFR inhibitors. This article translates preclinical findings into practical guidance for genotype-aware experiments and clinical-trial interpretation—while distinguishing promising hypotheses from established treatment evidence.

• Quizartinib (AC220): Testing FLT3 Dependence

  2026-09-26

  Quizartinib (AC220) is a potent FLT3 inhibitor for acute myeloid leukemia (AML) research. This article shows how to use FLT3 inhibition to distinguish target engagement from true pathway dependence—and how to interpret a related resistance mechanism reported in blast-phase CML.

• LDN-193189 Workflows for BMP Signaling Research

  2026-09-25

  Use LDN-193189 to test how BMP type I receptor activity contributes to epithelial signaling and phenotype—not as a stand-alone proof of pathway causality. This guide translates intestinal homeostasis findings into practical target-engagement, rescue, and troubleshooting workflows while emphasizing solubility and model-specific limits.

• A 83-01 ALK-5 Inhibitor in Trophoblast Workflows

  2026-09-25

  A 83-01 helps researchers test how Activin/Nodal and TGF-β receptor signaling shape stem-cell differentiation, including BMP4-driven trophoblast-like models. This guide translates a four-medium comparison into practical assay choices, dose controls, and troubleshooting steps without treating a multi-inhibitor protocol as proof of a single-compound effect.

• Crizotinib Hydrochloride as a Causal Probe

  2026-09-24

  Crizotinib hydrochloride is an ALK kinase inhibitor that can help researchers test how ALK, c-Met, or ROS1 activity contributes to tumor-cell behavior. This article focuses on experimental interpretation in patient-derived assembloids: separating target engagement from stromal effects and nonspecific changes in viability.

• Separating Growth Arrest From Cancer Cell Death

  2026-09-24

  Hannah Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central finding is that most drugs influence both proliferation and cell death, but the balance and timing differ—an important reason to measure these outcomes separately.

• From TGF-β Signaling to Cell Mechanics

  2026-09-23

  Cell mechanics and TGF-β-family signaling offer complementary ways to interrogate complex disease phenotypes—but they should not be conflated. This article explains what the MRTFA–KCNMB1 cancer-stiffness findings establish, where SB-505124 hydrochloride can strengthen fibrosis and signaling studies, and how to design experiments that distinguish pathway effects from mechanical outcomes.

• Reactive Oxygen Species Assay Kit Workflow

  2026-09-23

  Use the Reactive Oxygen Species Assay Kit to connect live-cell oxidative signals with tetrandrine-induced changes in black sea bream myogenic differentiation. This workflow emphasizes stage-specific controls, quantitative normalization, and practical troubleshooting rather than treating DCF fluorescence as a stand-alone mechanistic answer.

• Cichoric Acid and HIF-1α in Septic AKI

  2026-09-22

  The reference study identifies a macrophage-centered mechanism in which cichoric acid suppresses succinate dehydrogenase activity, HIF-1α-linked glycolysis, cytoskeletal acetylation, and NLRP3 inflammasome activation during sepsis-induced acute kidney injury. Its combination of LPS-challenged mice and RAW264.7 macrophages connects metabolic, mitochondrial, inflammatory, and renal outcomes, while also defining important limits for translation beyond the experimental model.

8069 records 1/538 page Next 12345 下5页 Last page